CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03703375
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-06-13T00:05:09.566253+00:00
Published At: 2024-07-08T00:00:00+00:00
Record Updated At: 2026-06-12
Results Posted At: 2024-07-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, T-Cell"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-06-12"
protocolSection.identificationModule.nctId: "NCT03703375"
protocolSection.identificationModule.officialTitle: "Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator\u0027s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-07-08"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.